(Q38040859)

27 August 2017

Nanotechnology based platforms for survivin targeted drug discovery (English)

1 reference

27 August 2017

0 references

1 reference

4

Jagat R Kanwar

1 reference

27 August 2017

Rasika M Samarasinghe

series ordinal

1

1 reference

27 August 2017

Jessica Gibbons

series ordinal

2

1 reference

27 August 2017

Rupinder K Kanwar

series ordinal

3

1 reference

27 August 2017

language of work or name

English

0 references

publication date

5 September 2012

1 reference

Expert Opinion on Drug Discovery

27 August 2017

1 reference

27 August 2017

7

1 reference

27 August 2017

11

1 reference

27 August 2017

1083-1092

1 reference

27 August 2017

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.719869

Caspases: the executioners of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.719869

Validating survivin as a cancer therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.719869

Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.719869

Compartmentalized phosphorylation of IAP by protein kinase A regulates cytoprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.719869

Targeting survivin in cancer: the cell-signalling perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.719869

Survivin signaling in clinical oncology: a multifaceted dragon

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.719869

Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.719869

Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: a clinical phase 1/2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.719869

Gene therapy -- promises, problems and prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.719869

Proliferative and protective effects of SurR9-C84A on differentiated neural cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.719869

Novel survivin mutant protects differentiated SK-N-SH human neuroblastoma cells from activated T-cell neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.719869

Survivin mutant protects differentiated dopaminergic SK-N-SH cells against oxidative stress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.719869

A cell-permeable dominant-negative survivin protein induces apoptosis and sensitizes prostate cancer cells to TNF-α therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.719869

Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.719869

Efficient inhibition of murine breast cancer growth and metastasis by gene transferred mouse survivin Thr34-->Ala mutant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.719869

Inhibition of human lung adenocarcinoma growth using survivint34a by low-dose systematic administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.719869

Therapeutic effects of survivin dominant negative mutant in a mouse model of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.719869

Enhancement of cisplatin sensitivity in Lewis Lung carcinoma by liposome-mediated delivery of a survivin mutant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.719869

RNAi-based therapeutics targeting survivin and PLK1 for treatment of bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.719869

Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.719869

Encapsulated plant extract (Gelsemium sempervirens) poly (lactide-co-glycolide) nanoparticles enhance cellular uptake and increase bioactivity in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.719869

Anticancer Potentials of Root Extract of Polygala senega and Its PLGA Nanoparticles-Encapsulated Form

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.719869

Antiangiogenic therapy using nanotechnological-based delivery system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.719869

Apoptotic mechanism of human leukemia K562/A02 cells induced by magnetic iron oxide nanoparticles co-loaded with daunorubicin and 5-bromotetrandrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.719869

In vivo imaging of siRNA delivery and silencing in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.719869

An antisense oligonucleotide carrier based on amino silica nanoparticles for antisense inhibition of cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.719869

Dendrimers as carriers for delivery of chemotherapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.719869

Dendrimers-delivered short hairpin RNA targeting hTERT inhibits oral cancer cell growth in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.719869

Dendrimer-modified magnetic nanoparticles enhance efficiency of gene delivery system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.719869

Toxic potential of materials at the nanolevel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.719869

Nanotoxicology and in vitro studies: the need of the hour

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.719869

Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.719869

Novel multifunctional nanoparticle mediates siRNA tumour delivery, visualisation and therapeutic tumour reduction in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.719869

10.1517/17460441.2012.719869

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference